About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

NeuroStar TMS Therapy Shows Promise as Maintenance Therapy for Major Depressive Disorder

by Bidita Debnath on May 12, 2014 at 11:14 PM
Font : A-A+

 NeuroStar TMS Therapy Shows Promise as Maintenance Therapy for Major Depressive Disorder

Neuronetics, Inc. announced results from a dual-arm randomized study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS TherapyŽ for Major Depressive Disorder (MDD).

Six weeks of acute NeuroStar TMS Therapy induced remission in 61.2 percent of all enrolled patients. At three months, 62.5 percent of medication-free patients randomized to once-monthly treatment with NeuroStar TMS Therapy maintained response as compared to 43.8 percent of patients who did not receive maintenance treatment. The complete findings will be presented at the 167th American Psychiatric Association Annual Meeting in New York City.

Advertisement

"This pilot study supports the notion that maintenance TMS may be useful in the prevention of recurrence of major depression and is an important step in learning what the optimum treatment parameters will be," said Scott Aaronson, M.D., Director of Clinical Research Programs, and Associate Medical Director at Sheppard Pratt. "This preliminary information will help define an approach to TMS as a maintenance therapy as we extend our understanding of the long-term usefulness of TMS in the treatment of people with this debilitating illness."

In the study, medication-free patients with a diagnosis of unipolar, non-psychotic MDD, who had failed to receive benefit from prior antidepressant medication were treated with 6 weeks of NeuroStar TMS Therapy; patients who met response criteria were randomized to either once monthly maintenance TMS treatments or monthly observation. Patients in either cohort could receive TMS reintroduction for protocol-defined symptomatic worsening. The primary outcome was the proportion of patients without symptomatic worsening throughout the three months of the maintenance treatment phase.
Advertisement

"As evidenced by this first pharmacotherapy-free maintenance trial, Neuronetics is committed to investing in continued research efforts that provide validation of NeuroStar TMS Therapy, and which may help better our understanding of depression and improve patients' therapeutic outcomes," said David Brock, M.D, Medical Director at Neuronetics.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
Toothache
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Reiki and Pranic Healing Holistic Management for Depression Quiz on Depression 

Recommended Reading
Depression Makes One-third People Struggle at Work: Study
A British survey has revealed that depression, stress or burn out are forcing one out of three ......
Physical Signs of Depression Common Among ICU Survivors: Study
Depression affects more than one out of three survivors of critical illness, and the majority of ......
Stress in Married Life Might Lead to Depression
A study by University of Wisconsin-Madison researchers and their colleagues says that marital ......
Depression Ups Heart Disease Risk
Depression is the risk factor for heart disease, says study....
Holistic Management for Depression
Depression is a common disorder and many worldwide suffer from depression. Early recognition of symp...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use